Vasilina A. Sergeeva

Vasilina A. Sergeeva

Auto-generated profile, based on publicly available information

Vasilina A. Sergeeva

Research Centre for Medical Genetics (RCMG), Moscow 115478, Russia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Journal of Molecular Biology
Verified
Journal Article
Closed access
ATAndrei Tereshchenkov
Andrei Tereshchenkov
MDMalgorzata Dobosz-Bartoszek
Malgorzata Dobosz-Bartoszek
IOIlya Osterman
Ilya Osterman
JMJames Marks
James Marks
VSVasilina A. Sergeeva
Vasilina A. Sergeeva
YPYury Polikanov
Yury Polikanov

Verified
Journal Article
Open access
PDF file
SSSvetlana Smirnikhina
Svetlana Smirnikhina
MZMilyausha I. Zaynitdinova
Milyausha I. Zaynitdinova
VSVasilina A. Sergeeva
Vasilina A. Sergeeva
ALAlexander Vyacheslavovich Lavrov
Alexander Vyacheslavovich Lavrov
Genome editing is currently widely used in biomedical research; however, the use of this method in the clinic is still limited because of its low efficiency and possible side effects. Moreover, the correction of mutations that cause diseases in humans seems to be extremely important and promising. Numerous attempts to improve the efficiency of homology-directed repair-mediated correction of mutations in mammalian cells have focused on influencing the cell cycle. Homology-directed repair is known to occur only in the late S and G2 phases of the cell cycle, so researchers are looking for safe ways to enrich the cell culture with cells in these phases of the cell cycle. This review surveys the main approaches to influencing the cell cycle in genome editing experiments (predominantly using Cas9), for example, the use of cell cycle synchronizers, mitogens, substances that affect cyclin-dependent kinases, hypothermia, inhibition of p53, etc. Despite the fact that all these approaches have a reversible effect on the cell cycle, it is necessary to use them with caution, since cells during the arrest of the cell cycle can accumulate mutations, which can potentially lead to their malignant transformation.

17 January 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
VSVasilina Sergeeva
Vasilina Sergeeva
OKOlga Kraevaya
Olga Kraevaya
EEElizaveta Ershova
Elizaveta Ershova
LKLarisa Kameneva
Larisa Kameneva
EMElena Mikhailovna Malinovskaya
Elena Mikhailovna Malinovskaya
SKSvetlana Kostyuk
Svetlana Kostyuk
Oxidative stress is a major issue in a wide number of pathologies (neurodegenerative, cardiovascular, immune diseases, and cancer). Because of this, the search for new antioxidants is an important issue. One of the potential antioxidants that has been enthusiastically discussed in the past twenty years is fullerene and its derivatives. Although in aqueous solutions fullerene derivatives have shown to be antioxidants, their properties in this regard within the cells are controversially discussed. We have studied two different water-soluble fullerene C60 and C70 derivatives on human embryonic lung fibroblasts at a wide range of concentrations. Both of them cause a decrease in cellular ROS at short times of incubation (1 hour). Their prolonged action, however, is fundamentally different: derivative GI-761 causes secondary oxidative stress whereas derivative VI-419-P3K keeps ROS levels under control values. To gain a better understanding of this effect, we assessed factors that could play a role in the response of cells to fullerene derivatives. Increased ROS production occurred due to NOX4 upregulation by GI-761. Derivative VI-419-P3K activated the transcription of antioxidant master regulator NRF2 and caused its translocation to the nucleus. This data suggests that the antioxidant effect of fullerene derivatives depends on their chemical structure.

1 July 2016 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
EEElizaveta Ershova
Elizaveta Ershova
VSV.A. Sergeeva
V.A. Sergeeva
ACA.I. Chausheva
A.I. Chausheva
DZDiana Zheglo
Diana Zheglo
VNV.A. Nikitina
V.A. Nikitina
SKS.V. Kostyuk
S.V. Kostyuk

1 January 2017 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
VSV A Sergeeva
V A Sergeeva
EEElizaveta Ershova
Elizaveta Ershova
NVN N Veiko
N N Veiko
EMElena Mikhailovna Malinovskaya
Elena Mikhailovna Malinovskaya
AKA A Kalyanov
A A Kalyanov
SKS V Kostyuk
S V Kostyuk
We have hypothesized that the adaptive response to low doses of ionizing radiation (IR) is mediated by oxidized cell‐free DNA (cfDNA) fragments. Here, we summarize our experimental evidence for this model. Studies involving measurements of ROS, expression of the NOX (superoxide radical production), induction of apoptosis and DNA double‐strand breaks, antiapoptotic gene expression and cell cycle inhibition confirm this hypothesis. We have demonstrated that treatment of mesenchymal stem cells (MSCs) with low doses of IR (10 cGy) leads to cell death of part of cell population and release of oxidized cfDNA. cfDNA has the ability to penetrate into the cytoplasm of other cells. Oxidized cfDNA, like low doses of IR, induces oxidative stress, ROS production, ROS‐induced oxidative modifications of nuclear DNA, DNA breaks, arrest of the cell cycle, activation of DNA reparation and antioxidant response, and inhibition of apoptosis. The MSCs pretreated with low dose of irradiation or oxidized cfDNA were equally effective in induction of adaptive response to challenge further dose of radiation. Our studies suggest that oxidized cfDNA is a signaling molecule in the stress signaling that mediates radiation‐induced bystander effects and that it is an important component of the development of radioadaptive responses to low doses of IR.

17 August 2017 in Biomedical Reports
Verified
Journal Article
Closed access
PDF file
EEElizaveta Ershova
Elizaveta Ershova
VSVasilina Sergeeva
Vasilina Sergeeva
MKMaria Klimenko
Maria Klimenko
KAKristina Avetisova
Kristina Avetisova
PKPeter Klimenko
Peter Klimenko
SKSvetlana Kostyuk
Svetlana Kostyuk
The level of apoptosis is increased during pregnancy. Dying cells emit DNA that remains in blood circulation and is known as cell‑free DNA (cfDNA). The concentration of cfDNA can reflect the level of cell death. The present article is the result of studying cfDNA concentration and DNase I activity in the blood plasma of 40 non‑pregnant women (control), 40 healthy pregnant women (over 37 weeks) and 40 pregnant women with a diagnosis of intrauterine growth restriction (IUGR). In order to explain the obtained results, a program modeling the change of cfDNA concentration under the influence of different internal and external factors was written. It was reported that, despite the fact that the level of cell death is increased, cfDNA concentration in blood can be decreased due to activation of cfDNA elimination system. A significant increase of DNase I activity has been reported in cases of IUGR. Increase in DNase I activity over a certain threshold indicates presence of pathological processes in the organism. CfDNA circulating in blood cannot be a reliable marker of increased cell death during pregnancy. Thus, assessment of the level of cell death during pregnancy should be done by simultaneous analysis of cfDNA level and DNase I activity.